• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Neurocrine Bioscienc (NQ: NBIX )

    121.21 -1.33 (-1.09%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,192,563
    Open 122.49
    Bid (Size) 118.20 (1)
    Ask (Size) 124.93 (1)
    Prev. Close 122.54
    Today's Range 119.92 - 123.64
    52wk Range 103.63 - 157.98
    Shares Outstanding 100,900,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag.
    NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a stock that provides good value for the fundamentals it showcases. 
    Via Chartmill
    Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio?
    10 worst performing large-cap stocks in the last week. Dollar General, Super Micro Computer, Okta, Pure Storage, Neurocrine Biosciences among them. 
    Via Benzinga

    Performance

    YTD
    -7.99%
    -7.99%
    1 Month
    -16.77%
    -16.77%
    3 Month
    -8.91%
    -8.91%
    6 Month
    -10.43%
    -10.43%
    1 Year
    +10.02%
    +10.02%

    More News

    Read More
    Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    Why Neurocrine Biosciences Stock Was Tumbling This Week
    Via The Motley Fool
    Evaluating Neurocrine Biosciences: Insights From 15 Financial Analysts
    Via Benzinga
    NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move.
    Via Chartmill
    Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
    Via Benzinga
    NVIDIA To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    Nasdaq Down Over 1%; Foot Locker Shares Tumble After Q2 Results
    Via Benzinga
    As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
    Via Benzinga
    US Stocks Mixed; JM Smucker Slashes Annual Guidance
    Via Benzinga
    NASDAQ:NBIX is not too expensive for the growth it is showing.
    Via Chartmill
    A Closer Look at 7 Analyst Recommendations For Neurocrine Biosciences
    Via Benzinga
    Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers
    Via Investor's Business Daily
    Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
    Via Benzinga
    Why the quality investor may take a look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).
    Via Chartmill
    9 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    New Study Reveals How Classical Music Could Revolutionize Depression Care
    Via PressReach
    Exposures Product Safety
    NASDAQ:NBIX, a strong growth stock, setting up for a breakout.
    Via Chartmill
    So Much For Expecting The Fed To Stick The Landing
    Via Talk Markets
    Topics Economy
    Exposures Interest Rates
    Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
    Via Investor's Business Daily
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    NASDAQ:NBIX, a growth stock which is not overvalued.
    Via Chartmill
    Should Quality Investors Include NASDAQ:NBIX in Their Portfolio?
    Via Chartmill
    Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences
    Via Benzinga
    Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation.
    Via Chartmill
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.